Mass vaccination campaigns have dramatically reshaped public health across the African continent. These large-scale immunization efforts, targeting populations from bustling cities to remote rural villages, have achieved historic milestones—such as the eradication of smallpox—and continue to prevent millions of deaths from preventable diseases. Examining the history of these campaigns reveals both profound successes and enduring challenges, offering critical lessons for future health interventions.

Early Vaccination Efforts in Colonial and Post-Independence Africa

The roots of mass vaccination in Africa stretch back to the early 20th century, often tied to colonial health systems focused on protecting European administrators and labor forces. Early campaigns against smallpox and yellow fever used rudimentary methods like arm-to-arm transfer of material or crude vaccines. These efforts were sporadic, under-resourced, and rarely reached the majority of indigenous populations. For example, in French West Africa, vaccination teams targeted only port cities and administrative centers, leaving vast rural areas uncovered.

Following independence in the 1950s and 1960s, newly formed African governments prioritized public health as a pillar of nation-building. The World Health Organization (WHO) and other international bodies began supporting national immunization programs. A landmark early success was the Intensified Smallpox Eradication Programme, launched by the WHO in 1967. Through a combination of mass vaccination and innovative surveillance and containment strategies (surveillance-containment), the campaign achieved what many thought impossible: the global eradication of smallpox, certified in 1980. Africa was a central battleground in this fight, with rigorous campaigns in countries like Ethiopia, Somalia, and Sudan. The last naturally occurring cases in Africa were tracked and contained, demonstrating the power of community-based surveillance.

Simultaneously, the Expanded Programme on Immunization (EPI) was established by the WHO in 1974 to ensure that all children worldwide had access to routine vaccines against diphtheria, tetanus, pertussis, polio, measles, and tuberculosis (BCG). Across Africa, EPI provided the foundational infrastructure for future mass campaigns, including cold chain networks, trained health workers, and community education programs. By the 1980s, even countries with fragile health systems had established basic EPI programs, often with support from UNICEF and bilateral donors.

Major Mass Vaccination Campaigns and Targeted Diseases

From the 1980s onward, Africa saw a series of large-scale, disease-specific campaigns. Each brought distinct strategies and outcomes. The following subsections highlight the most impactful campaigns.

Polio: The Global Polio Eradication Initiative (GPEI)

Launched in 1988, the GPEI aimed to rid the world of polio. Africa became a major focus as the disease remained endemic in several countries, including Nigeria, the Democratic Republic of the Congo (DRC), and Somalia. The campaign employed National Immunization Days (NIDs) where children under five were given oral polio vaccine house-to-house and at fixed posts. Despite immense logistical hurdles—civil war in Nigeria and Somalia, difficult terrain, and persistent rumors about vaccine safety—the continent made extraordinary progress. The last case of wild poliovirus in Africa was recorded in Nigeria in August 2016, and in 2020 the African region was officially declared wild poliovirus-free by the African Regional Certification Commission. However, challenges remain with circulating vaccine-derived poliovirus (cVDPV) in countries like the DRC and Nigeria, requiring continued vigilance and targeted campaigns using novel oral polio vaccines.

Measles: Reducing a Major Killer

Measles, once a leading cause of child mortality in Africa, has been targeted by massive catch-up campaigns. The Measles & Rubella Initiative, launched in 2001, supported supplementary immunization activities (SIAs) that vaccinated hundreds of millions of children across the continent. In Africa, these campaigns involved door-to-door delivery, mobile vaccination posts, and mass media mobilization. The result was a dramatic reduction in measles deaths—the WHO estimates that between 2000 and 2016, measles mortality in Africa dropped by roughly 86%. Outbreaks still occur due to gaps in routine immunization, but mass campaigns remain the primary tool for closing these gaps. In 2022, large outbreaks were reported in Zimbabwe, Ghana, and Ethiopia, sparking emergency SIAs that reached millions of unvaccinated children.

Yellow Fever: Preventative Campaigns

Yellow fever is endemic in many African countries, causing periodic outbreaks. The WHO's Eliminate Yellow Fever Epidemics (EYE) strategy, launched in 2017, coordinates mass preventive vaccination campaigns in high-risk areas. These campaigns often target entire districts (or even entire countries) with a single dose of live attenuated yellow fever vaccine. Successes include the mass vaccination of over 800 million people in Africa by 2026 target, using routine immunization and reactive campaigns to stop outbreaks in Angola and the Democratic Republic of Congo. These campaigns rely heavily on cold chain management to keep the vaccine temperature-sensitive and have driven innovations in solar refrigeration for remote health posts.

Meningitis A: The MenAfriVac Revolution

Meningococcal meningitis A was a major cause of epidemics in the African meningitis belt, a region stretching from Senegal to Ethiopia. In 2010, the MenAfriVac vaccine—developed specifically for Africa through a partnership led by the WHO and PATH—was introduced via mass campaigns. By 2021, over 330 million people had been vaccinated, and the target group (people aged 1–29) had been covered in all 26 countries of the belt. The impact was striking: subsequent meningitis A epidemics all but disappeared, a success story that has inspired similar efforts for other serogroups like meningococcus X.

Ebola: Ring Vaccination and Community Engagement

The devastating 2014-2016 West African Ebola outbreak prompted an unprecedented response. For the first time, an experimental Ebola vaccine (rVSV-ZEBOV) was deployed in a novel ring vaccination strategy—vaccinating contacts and contacts of contacts of known cases, creating a protective "ring" of immunity. This method, later used in the Democratic Republic of the Congo (DRC) outbreaks, proved highly effective. The DRC's 2018-2020 outbreak saw the vaccination of over 400,000 people using ring vaccination and targeted geographic mass vaccination. Community engagement and trust-building were critical to overcome initial vaccine hesitancy and ensure uptake. Health workers often had to negotiate with armed groups to reach affected communities.

COVID-19: The Largest Vaccination Campaign in History

The COVID-19 pandemic triggered the largest and fastest vaccine roll-out across Africa. African countries, many with fragile health systems, faced immense challenges: securing vaccine doses that often arrived late through COVAX and bilateral deals; logistical hurdles for ultra-cold storage (Pfizer-BioNTech) or standard cold chain (AstraZeneca, Johnson & Johnson, Sinopharm); and combating widespread misinformation. Despite slow initial uptake, campaigns innovated with mobile vaccination units, workplace and school-based vaccination, and leveraging existing polio and measles campaign infrastructure. By mid-2024, many African countries had vaccinated over 50% of their adult population, but stark disparities remain between urban and rural areas and between nations. The pandemic also accelerated the push for local vaccine manufacturing, a topic covered later in this article.

Key Outcomes and Measurable Impact

The outcomes of mass vaccination campaigns across Africa have been transformative, saving tens of millions of lives and reshaping disease patterns.

Disease Eradication and Elimination

  • Smallpox eradicated (1980) – the only human disease ever eradicated, with Africa as a key battleground.
  • Wild poliovirus eliminated from the African region (2020), certified by the African Regional Certification Commission.
  • Maternal and neonatal tetanus eliminated in over 40 African countries through campaigns targeting women of childbearing age with tetanus toxoid.
  • Measles mortality reduced by more than 80% since 2000, from an estimated 550,000 deaths to under 100,000 annually in the African region.
  • Meningococcal meningitis A epidemics controlled through mass MenAfriVac campaigns, with zero confirmed cases in vaccinated populations since 2017.
  • Yellow fever outbreaks contained through reactive and preventive campaigns, reducing case fatality rates in outbreak settings.

Reduction in Childhood Mortality

Studies estimate that vaccination campaigns have saved millions of African lives since 2000. For every dollar spent on immunization, the return on investment in Africa is estimated at $20–$30 in averted health costs, productivity gains, and reduced disability. The expansion of coverage has contributed to a steep decline in under-5 mortality rates across the continent—from 179 deaths per 1,000 live births in 1990 to around 74 per 1,000 in 2020—with vaccines playing a central role.

Strengthened Health Systems

Mass campaigns have built lasting infrastructure: cold chain equipment, disease surveillance systems, trained health workforce, and supply chain management. These assets are now used for routine immunization, child health days, malaria bed net distribution, and outbreak response. For example, the polio eradication program's global surveillance network now supports the detection of many other diseases, including Ebola, measles, and yellow fever.

Challenges and Barriers to Success

Despite these achievements, mass vaccination campaigns in Africa have faced—and continue to face—significant obstacles that threaten progress.

Logistical Hurdles

Geographic barriers like mountains, deserts, and flooded areas during rainy seasons make last-mile delivery difficult. Inadequate cold chain (especially for vaccines requiring -60°C to -80°C like the Ebola and Pfizer COVID-19 vaccines) remains a bottleneck. Political instability and armed conflicts in regions like the Sahel, parts of the DRC, and the Horn of Africa have disrupted vaccination campaigns, leaving children vulnerable to outbreaks. In conflict zones, health workers face kidnapping threats, and health facilities are often targeted or looted.

Vaccine Hesitancy and Misinformation

Misinformation—often spread via social media, religious leaders, or political actors—has fueled distrust. During polio campaigns in Nigeria, rumors that the vaccine caused infertility or was a Western plot led to low uptake and subsequent outbreaks. Similarly, COVID-19 vaccines faced widespread skepticism linked to conspiracy theories about altering DNA or government surveillance. Combating hesitancy requires sustained community engagement, trusted local messengers, transparent communication, and culturally sensitive dialogue. In 2023, Gavi and partners launched initiatives to train community leaders in counternarratives.

Financial and Political Sustainability

Mass campaigns are expensive. Donor funding from Gavi, the Vaccine Alliance, and bilateral partners has been critical but is not guaranteed forever. As African economies grow, there is increasing pressure for countries to co-finance and eventually self-finance their immunization programs. Political instability can halt campaigns overnight and set back years of progress. For instance, the Ebola vaccination campaign in the DRC was repeatedly interrupted by armed conflict, requiring creative ceasefire agreements to reach vulnerable populations.

Innovations Driving Future Success

Mobile Clinics and Solar Refrigeration

To reach pastoralist and nomadic populations, innovative approaches like mobile vaccination teams on motorcycles or with boats are used. Solar-powered refrigerators are now common, allowing vaccines to be stored safely in off-grid health posts. Digital tools—electronic immunization registries, biometric tracking of children, and GPS trackers mapping vaccination teams—are improving coverage rates and reducing dropouts. In Kenya, the use of electronic immunization registries has increased data timeliness and reduced vaccine stockouts.

Integrated Campaigns

Increasingly, mass vaccination is bundled with other health interventions: vitamin A supplementation, deworming, bed net distribution, and nutrition screening. This "integrated campaign" approach reduces costs, improves attendance, and delivers broader health impact. In Nigeria, integrated campaigns have reached millions of children who would otherwise miss out on multiple interventions.

New Vaccine Technologies

Africa is set to benefit from newer vaccines. The malaria vaccine (RTS,S/AS01) is now being rolled out in Ghana, Kenya, Cameroon, and Malawi, with plans to reach millions of children. A second malaria vaccine (R21/Matrix-M) promises even more affordable and large-scale production. The first-ever typhoid conjugate vaccine campaign began in Zimbabwe in 2022, targeting over 200,000 children.in 2023, the RTS,S malaria vaccine was integrated into routine childhood immunization in three pilot countries, and a large-scale mass campaign is planned for 2024–2025 in high-burden areas.

Local Manufacturing

The COVID-19 pandemic exposed Africa's heavy dependence on imported vaccines (90% of vaccine doses were imported pre-pandemic). Several initiatives are now underway to boost local vaccine manufacturing: the African Union's Partnership for African Vaccine Manufacturing (PAVM) aims to produce 60% of Africa's vaccine needs by 2040. Countries like Senegal, South Africa, Rwanda, and Kenya are building production facilities. In 2023, the first mRNA vaccine technology transfer hub was established in South Africa, with a goal of producing vaccines for COVID-19 and other diseases. Local manufacturing will reduce supply chain vulnerabilities and enable faster deployment of campaign vaccines in future pandemics.

Future Perspectives: Strengthening Routine Immunization

The long-term vision for mass vaccination in Africa is not a reliance on repeated campaigns as a catch-up method. Instead, the goal is to strengthen routine immunization so that high coverage is maintained year-round. Campaigns will remain essential for outbreak response, for reaching missed children, and for introducing new vaccines. But the ultimate success measure will be a sustainable, country-owned immunization system that protects every child.

The COVID-19 pandemic demonstrated both the power of rapid, global collaboration (development of vaccines in under a year) and the profound inequities in access. Moving forward, Africa must leverage its lessons: invest in cold chain, train and retain health workers, combat misinformation with trusted community voices, and diversify vaccine sources through local production. The history of mass vaccination in Africa is one of extraordinary progress built on tireless effort, scientific innovation, and political will. Continued commitment from African governments, international partners, and communities will ensure that the next chapter is even more successful, saving millions more lives and building a healthier continent for generations to come.